Article

Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis—Results from the Adjuvant SUCCESS A Trial

Elisabeth K. Trapp 1,*, Peter A. Fasching 2, Tanja Fehm 3, Andreas Schneeweiss 4, Volkmar Mueller 5,*, Nadia Harbeck 6,*, Ralf Lorenz 7, Claudia Schumacher 8, Georg Heinrich 9, Fabienne Schochter 10,*, Amelie de Gregorio 10, Marie Tzschaschel 10, Brigitte Rack 10, Wolfgang Janni 10 and Thomas W. P. Friedl 10

1 Department of Gynecology and Obstetrics, Medical University of Graz, 8036 Graz, Austria
2 Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, 91054 Erlangen, Germany
3 Department of Gynecology and Obstetrics, University Hospital Dusseldorf, Heinrich-Heine University Dusseldorf, 40225 Düsseldorf, Germany
4 National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, 69120 Heidelberg, Germany
5 Department of Gynecology, University Hospital Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
6 Breast Center, Department of Gynecology and Obstetrics and CCC Munich, LMU University Hospital, 81337 München, Germany
7 Gynecologic Practice Dr. Lorenz, N. Hecker, Dr. Kreise-Sender, 38100 Braunschweig, Germany
8 Department of Gynecology and Obstetrics, St. Elisabeth’s Hospital, 50935 Cologne, Germany
9 Oncological Practice, 15517 Fürstenwalde, Germany
10 Department of Gynecology and Obstetrics, University Hospital Ulm, 89081 Ulm, Germany

* Correspondence: elisabeth.trapp@medunigraz.at

Abstract: The prognostic relevance of circulating tumor cells (CTCs) in breast cancer is well established. However, little is known about the association of CTCs and site of first metastasis. In the SUCCESS A trial, 373 out of 3754 randomized high-risk breast cancer patients developed metastatic disease. CTC status was assessed by the FDA-approved CellSearch®-System (Menarini Silicon Biosystems, Bologna, Italy) in 206 of these patients before chemotherapy and additionally in 159 patients after chemotherapy. CTCs were detected in 70 (34.0%) of 206 patients before chemotherapy and in 44 (27.7%) of 159 patients after chemotherapy. CTC-positive patients who were CTC-negative both before and after chemotherapy were more likely to show bone-only first distant disease (37.5% vs. 21.0%) and first distant disease at multiple sites (31.3% vs. 12.6%) than patients without CTCs. These data indicate that CTCs might serve as a liquid biopsy surveillance-marker enabling risk-stratification for deciding on further adjuvant add-on-treatment.

Cancers 2022, 14, 3949. https://doi.org/10.3390/cancers14163949

Published: 16 August 2022
Accepted: 9 August 2022
Published: 16 August 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Keywords: liquid biopsy; circulating tumor cells (CTC); breast cancer; metastasis

1. Introduction

Breast cancer is the most common cancer in women. Although mortality rates have declined since 1989, recent data indicate that the incidence of breast cancer is rising [1]. While breast cancer remains curable in stages I–III, the main goal of treatment in stage IV remains as extending time with the best possible quality of life. Therefore, metastasis still represents the limit of curable disease.

Furthermore, metastatic disease remains the principal cause of breast-cancer-related death [2,3].

To metastasize, a multi-step process termed metastatic cascade is started at the primary tumor site. In the first step, single tumor cells invade the surrounding tissue and then enter the circulatory and lymphatic system. Therefore, these shedding cells have to escape the immune system and survive surrounded by mesenchymal environment [4].

Epithelial-to-mesenchymal plasticity resembles the key to develop into disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) [5]. These micro-metastatic lesions may enter distant organs like seeds in the soil and stay quiescent in their metastatic niche and/or reactivate, promoting metastasis [6,7].

Several clinical studies have demonstrated the prognostic value of CTC detection before, during, and after completion of chemotherapy both in metastatic and early breast cancer [8–10]. Furthermore, it has been shown that positive CTC status during follow-up of high-risk early breast cancer survivors is associated with poor prognosis [11,12].

Over the years, screening-based early breast cancer detection and modern multidisciplinary treatment modalities have improved survival prospects for breast cancer patients constantly [13,14]. Facing the increasing number of breast cancer survivors, follow-up strategies integrating novel prognostic factors to classify breast cancer patients into “risk classes” are lacking [15]. So far, large surveillance trials have failed to demonstrate survival improvements by intensified follow-up [16]. Accordingly, all risk groups are followed up in the same way [17–20]. However, advances in breast cancer research such as the development of new chemotherapeutics and endocrine or targeted therapies as well as PDL1-, TROP-2, PARP-, and CDK4/6-inhibitors have rendered multiple new and well-tolerated treatment options demonstrating survival benefits in high-risk breast cancer patients. Some of these therapeutics have already made their way into adjuvant add-on treatments for high-risk breast cancer survivors [21–25]. The use of these add-on treatment options is based on the perceived recurrence risk of patients, which is traditionally assessed using clinical data on patients’ age, tumor subtype, tumor size, tumor response to neoadjuvant treatment, lymph node involvement, and pathological grade and type. More recently, risk has been additionally assessed using genomic tests which are intended to complement risk assessment based on traditional clinico-pathological parameters but are only available for certain cancer subtypes. However, data are accumulating that additional markers with better prognostic and predictive value are needed to identify patients who benefit most from additional add-on adjuvant treatment options that enter a clinical routine. As these treatments may cause serious side effects, individual patient risk has to be assessed in the most accurate way, to not only prevent undertreatment, but equally important, to avoid ineffective overtreatment [26–28].

Identifying clear high-risk breast cancer patients and offering further adjuvant treatment strategies, therefore, leads to the question of whether early detection and treating micro-metastatic disease might improve survival and may help to prevent symptomatic and overt metastatic disease. Studies regarding treatments targeting DTC and CTC provided conflicting data about the predictive value of micro-metastasis in prospective trial settings [29–32]. While CTCs showed to be a promising prognostic tool for identifying patients at risk for tumor relapse throughout treatment and follow-up, it is unknown whether
the presence of CTCs may also indicate the future site of metastatic lesions. If indeed, the presence of CTCs points not only to a higher risk of relapse but also to a higher likelihood of disease recurrence at specific sites, this may help to decide on new or additional targeted surveillance and/or treatment options, which down the road might prevent or at least delay overt metastatic disease.

2. Methods

2.1. Study Design

SUCCESS A (NCT 02181101) is a phase III, randomized, prospective, multicenter open label trial with a $2 \times 2$ factorial design to evaluate the benefit of adding gemcitabine to adjuvant breast cancer chemotherapy and the benefit of extended adjuvant bisphosphonate treatment for five years. The study included 3754 patients who were first randomized to receive either three cycles of epirubicin, fluorouracil, or cyclophosphamide (FEC, 500/100/500 mg/m$^2$, q3w) followed by three cycles of docetaxel (Doc, 100 mg/m$^2$, q3w) or three cycles of FEC (500/100/500 mg/m$^2$, q3w) followed by three cycles of docetaxel and gemcitabine (DocG, docetaxel 75 mg/m$^2$ q3w plus gemcitabine 1000 mg/m$^2$ d1,8 q3w). After completion of chemotherapy, patients were subject to a second randomization to compare two versus five years of adjuvant zoledronate treatment (4 mg intravenously every 3 months for 2 years versus 4 mg intravenously every 3 months for 2 years followed by 4 mg intravenously every 6 months for 3 years). All trial patients were treated according to national German guidelines regarding endocrine and radiotherapy treatment as well as HER2 targeted therapy, if applicable. More information regarding the study design and the main outcomes with respect to the first and second randomization can be found in the works of De Gregorio et al. (2020) and Friedl et al. [33,34].

The trial was approved by 37 German ethical boards (the main ethics board was Ludwig-Maximilians-University Munich; positive ethics vote 076/05) and conducted between September 2005 (first patient in) and September 2014 (last patient out). The trial was conducted according to Good Clinical Practice guidelines and the Declaration of Helsinki, and all SUCCESS A patients provided written informed consent.

2.2. Patients

Eligibility for SUCCESS A required high-risk node-negative (grade 3, negative ER/PR status, age $\leq$ 35 years or tumor size $\geq$ pT2) or node-positive invasive breast cancer. Metastatic disease had to be excluded by clear chest X-ray, ultrasound of the abdomen, as well as bone scintigraphy before randomization. The tumor was staged according to the AJCC tumor node metastasis (TNM) system [35] and the histopathological grading [36] was determined in accordance with the Bloom–Richardson system. Receptor status was assessed by immunohistochemistry (IHC). HER2-status was defined positive if membranous staining was strong (IHC 3+) or if immunohistochemical membranous staining was moderate (IHC 2+) and additional HER2-based fluorescence in situ hybridization (FISH) testing was positive. Estrogen- and progesterone-receptor-positivity was assessed by immunohistochemical nuclear staining, and hormone receptor status was classified as positive if 10% of the investigated cells stained for at least one of the two receptors. All randomized patients underwent surgery with lymph node evaluation, comprising breast-conserving techniques as well as mastectomy, resulting in R0. Metastatic disease was assessed by routine follow-up care according to national German guidelines comprising clinical examinations at 3-month intervals for the first 2 years, every 6 months during the subsequent 3 years, and yearly thereafter, mammography every 12 months, and symptom-driven additional examinations.

2.3. CTC Detection

The adjunct translational research program of the SUCCESS A trial included determination of CTC status at four predefined timepoints (before chemotherapy, immediately after chemotherapy, two years after chemotherapy, and five years after chemotherapy).
Evaluation of CTC status required written informed consent by the patients to voluntarily participate in this adjunct translational project, which was, however, not mandatory for inclusion in the SUCCESS A study. As some patients refused, CTC status could not be assessed in all SUCCESS A patients. CTC evaluation was performed using the semi-automated FDA-approved CellSearch® system (Menarini Silicon Biosystems, Bologna, Italy; formerly Janssen Diagnostics) as described in detail elsewhere [9,10,37]. Briefly, CTC enumeration was achieved by immunomagnetic enrichment targeting the epithelial cell adhesion molecule (EpCAM). CTCs automatically pre-selected by the CellSearch® system as cytokeratin- and EpCAM-positive nucleated cells lacking CD45 were reviewed by two independent investigators for a final assessment of CTC status. A blood sample was defined as CTC-positive if at least one CTC was detected in 30 mL of peripheral blood.

2.4. Statistical Analysis

Descriptive statistics for all the categorical data are summarized with absolute and relative frequencies, while continuous variables are described using median and range. Group comparisons were performed using the Mann–Whitney U test (two groups) or the Kruskal–Wallis test (more than two groups) for continuous variables and the Cochran–Armitage test for trend or the Chi square test for the categorical variables. Associations between the CTC status and site of first metastatic disease were analyzed with the Chi square test.

Patient outcomes were analyzed in terms of distant disease-free survival (DDFS) and overall survival (OS). DDFS was defined as the time from randomization to distant disease recurrence or death from any cause or to the last date of adequate tumor assessment. OS was defined as the time from randomization to death from any cause or to the last date on which the patient was known to be alive. Survival rates based on time-to-event data were estimated by the Kaplan–Meier product limit method and survival curves were presented using Kaplan–Meier survival plots and compared using log-rank tests.

SPSS (IBM, New York, NY, USA) statistical software package, version 24, was used for statistical analysis. All statistical tests were two-tailed and \( p \) values < 0.05 were considered significant; there was no adjustment of the significance level for multiple comparisons.

3. Results

3.1. Patient Characteristics

Median follow-up time in the SUCCESS A study was 64 months. In total, 373 (9.9%) of the 3754 SUCCESS A patients developed metastatic disease (median time from randomization until the occurrence of the first metastatic disease within 30.0 months). An amount of 206 (55.2%) of these 373 patients gave their consent for participation in the translational research project and had data on CTC status prior to chemotherapy availability—these 206 patients were included in the analysis. An additional CTC assessment after chemotherapy was available for 159 (77.2%) of the 206 patients.

The median age of the 206 included patients was 55 years (range 27 to 75 years) and the median body mass index was 26.2 kg/m\(^2\) (range 18.5 to 47.0 kg/m\(^2\)). There were 78 (37.9%) and 128 (62.1%) pre- and postmenopausal patients, respectively. In 114 (55.3%) patients, breast-conserving tumorectomy was performed, while 92 (44.7%) patients underwent mastectomy for achieving R0 status. Overall, 123 (59.7%) patients were hormone-receptor-positive (estrogen receptor only, progesterone receptor only, and both estrogen and progesterone receptor positively stained in 27, 13, and 83 patients, respectively), and 45 (21.8%) patients had an HER2-positive primary tumor. According to the SUCCESS A inclusion criteria demanding high-risk tumors for randomization, most breast cancers were graded poorly differentiated (G3) or moderately differentiated (G2) with 132 (64.1%) and 71 (34.5%) of the cases, respectively. Histological tumor types were invasive ductal in 166 (80.6%), invasive lobular in 29 (14.1%), and other (e.g., medullary or papillary invasive breast cancer) in 11 (5.3%) patients. More details regarding patient and tumor characteristics are given in Table 1. Importantly, the 206 patients with distant recurrence
and known CTC status at baseline included in this analysis did not differ significantly from
the 167 patients with distant recurrence but unavailable CTC status at baseline with regard
to patient or tumor characteristics, with the exception of histological grading (Table 1).

Table 1. Baseline characteristics and clinicopathological variables of patients with early breast cancer recruited in the SUCCESS A trial who developed distant disease according to CTC assessment at baseline before the start of adjuvant chemotherapy (yes/no).

| Variable                              | Yes n = 206 | No n = 167 | p-Value 1 |
|--------------------------------------|-------------|------------|-----------|
| Age (years)                          |             |            |           |
| Median                               | 55          | 54         | 0.279 2   |
| Range                                | 27–75       | 26–86      |           |
| Body mass index (kg/m²)              |             |            |           |
| Median                               | 26.2        | 25.9       | 0.420 2   |
| Range                                | 18.5–47.0   | 16.7–44.9  |           |
| Tumor stage                          |             |            |           |
| pT1                                  | 57 (27.7%)  | 49 (29.3%) | 0.463 3   |
| pT2                                  | 121 (58.7%) | 100 (59.9%)|           |
| pT3                                  | 20 (9.7%)   | 13 (7.8%)  |           |
| pT4                                  | 8 (3.9%)    | 5 (3.0%)   |           |
| Nodal stage                          |             |            |           |
| pN0                                  | 44 (21.4%)  | 36 (21.6%) |           |
| pN1                                  | 79 (38.3%)  | 60 (35.9%) | 0.693 3   |
| pN2                                  | 42 (20.4%)  | 34 (20.4%) |           |
| pN3                                  | 41 (19.9%)  | 37 (22.2%) |           |
| Histological grading                 |             |            |           |
| G1                                   | 3 (1.5%)    | 3 (1.8%)   | 0.042 3   |
| G2                                   | 71 (34.5%)  | 75 (44.9%) |           |
| G3                                   | 132 (64.1%) | 89 (53.3%) |           |
| Histological type                    |             |            |           |
| ductal                               | 166 (80.6%) | 141 (84.4%)| 0.411 4   |
| lobular                              | 29 (14.1%)  | 16 (9.6%)  |           |
| other                                | 11 (5.3%)   | 10 (6.0%)  |           |
| Hormone receptor status              |             |            |           |
| negative                             | 83 (40.3%)  | 81 (48.5%) | 0.112 4   |
| positive                             | 123 (59.7%) | 86 (51.5%) |           |
| HER2 status                          |             |            |           |
| negative                             | 158 (76.7%) | 122 (73.1%)| 0.332 4   |
| positive                             | 45 (21.8%)  | 44 (26.3%) |           |
| unknown                              | 3 (1.5%)    | 1 (0.6%)   |           |
| Menopausal status                    |             |            |           |
| premenopausal                        | 78 (37.9%)  | 69 (41.3%) | 0.497 4   |
| postmenopausal                       | 128 (62.1%) | 98 (58.7%) |           |
| Type of surgery                      |             |            |           |
| breast conserving                    | 114 (55.3%) | 96 (57.5%) | 0.678 4   |
| mastectomy                           | 92 (44.7%)  | 71 (42.5%) |           |
| Adjuvant chemotherapy arm            |             |            |           |
| FEC-DocG                             | 100 (48.5%) | 78 (46.7%) | 0.724 4   |
| FEC-Doc                              | 106 (51.5%) | 89 (53.3%) |           |
| Zoledronate treatment arm            |             |            |           |
| 5 years                              | 107 (51.9%) | 76 (45.5%) | 0.217 4   |
| 2 years                              | 99 (48.1%)  | 91 (54.5%) |           |
Table 1. Cont.

| Variable                        | Yes | No | p-Value 1 |
|---------------------------------|-----|----|-----------|
| **Radiotherapy**                |     |    |           |
| no                              | 20  | 19 | 0.600 4   |
| yes                             | 186 | 148|           |
| **Endocrine therapy**           |     |    |           |
| no                              | 70  | 67 | 0.2214    |
| yes                             | 136 | 100|           |
| **HER2-targeted therapy**       |     |    |           |
| no                              | 164 | 128| 0.490 4   |
| yes                             | 42  | 39 |           |
| **Site of first metastatic disease** |   |    |           |
| Bone only                       | 44  | 33 | 0.260 4   |
| Visceral only                   | 60  | 37 |           |
| Single other site only          | 74  | 76 |           |
| Multiple sites                  | 28  | 21 |           |
| 1 All tests without unknowns; 2 Mann–Whitney U test; 3 Cochran–Armitage test for trend; 4 Chi-square test; 5 FEC-DocG: 3 cycles of fluorouracil-epirubicin-cyclophosphamide followed by 3 cycles of docetaxel and gemcitabine; FEC-Doc: 3 cycles of fluorouracil-epirubicin-cyclophosphamide followed by 3 cycles of docetaxel.

3.2. CTC Status before and after Chemotherapy

Of the 206 SUCCESS A patients who developed metastatic disease and for whom CTC status was assessed prior to chemotherapy, 136 (66.0%) were CTC-negative and 70 (34.0%) were CTC-positive. The number of CTCs detected in 30 mL of blood ranged from 1 to 827 CTCs (median 2 CTCs). Of the 159 patients with CTC assessment both before and after chemotherapy, CTC status before chemotherapy was negative for 107 (67.3%) patients and positive for 52 (32.4%) patients (median 2 CTCs, range 1–827 CTCs). After chemotherapy, 115 (72.3%) patients were CTC-negative and 44 (27.7%) patients were CTC-positive (median 1 CTC, range 1–124 CTCs). Combining CTC status prior to and after completion of chemotherapy revealed four different CTC change groups: 79 (49.7%) patients had no CTCs at both timepoints (neg/neg), 28 (17.6%) patients were CTC-negative before but CTC-positive after chemotherapy (neg/pos), 36 (22.6%) patients switched from CTC-positive before chemotherapy to CTC-negative after chemotherapy (pos/neg), and 16 (10.1%) were CTC-positive at both timepoints (pos/pos).

3.3. Localisation of First Metastatic Disease

Among the 206 SUCCESS A patients that developed metastatic disease and had a CTC assessment, first metastasis predominantly occurred in visceral sites (lung, liver), accounting for 60 (29.1%) patients. Bone-only first metastatic disease was documented in 44 (21.4%) patients. Other sites of first metastasis (including CNS/brain, lymphogenic sites comprising any lymph node other than supra-, infraclavicular, or axillary or adjacent to the internal mammary artery, pleura, skin, and ovary) were observed in 74 (35.9%) patients. In 28 (13.6%) patients, first metastatic disease was observed in multiple sites at the same time. The distribution of sites of first metastatic lesions (bone only, visceral only, single other site only, multiple sites) did not differ between the 206 SUCCESS A patients with CTC assessment included in the study and the remaining 167 SUCCESS A patients with distant disease without CTC assessment (see Table 1).

3.4. Distant Disease-Free Survival (DDFS) and Overall Survival (OS) According to Site of First Metastatic Disease

Figure 1 shows the Kaplan–Meier survival plots for DDFS according to the location of first metastatic disease for the 206 patients included in the study. Median DDFS was...
29.3 months for bone only, 37.5 months for visceral only, 35.7 months for other site only, and 29.9 months for multiple sites; however, these differences were not statistically significant (log-rank test, \( p = 0.342 \)).

![Figure 1. Distant disease-free survival according to the site of first metastatic disease.](image)

Overall survival according to the location of first metastatic disease is shown in Figure 2. Patients with first metastatic disease at multiple sites had significantly shorter OS (median 42.0 months) compared to patients with bone-only first metastatic disease (median 68.7 months; log-rank test pairwise comparison: \( p = 0.014 \)), patients with visceral-only first metastatic disease (median 63.6 months; log-rank test pairwise comparison: \( p = 0.016 \)), and patients with first metastatic disease at other sites only (median 67.5 months; log-rank test pairwise comparison: \( p = 0.003 \)). No significant differences with regard to OS were found between patients with bone-only, visceral only, and other site only first metastatic disease (log-rank test pairwise comparisons: all \( p > 0.40 \)).
OS (median 42.0 months) compared to patients with bone-only first metastatic disease (median 68.7 months; log-rank test pairwise comparison: $p = 0.014$), patients with visceral-only first metastatic disease (median 63.6 months; log-rank test pairwise comparison: $p = 0.016$), and patients with first metastatic disease at other sites only (median 67.5 months; log-rank test pairwise comparison: $p = 0.003$). No significant differences with regard to OS were found between patients with bone-only, visceral only, and other site only first metastatic disease (log-rank test pairwise comparisons: all $p > 0.40$).

Figure 2. Overall survival according to the site of first metastatic disease.

Similar results for DDFS and OS were obtained when only the 159 patients with CTC assessments both before and after chemotherapy were analyzed. DDFS did not differ significantly among the locations of first metastatic disease (bone only, visceral only, single other site only, multiple sites; log-rank test, $p = 0.259$), but OS did show significant differences among the four locations of first metastatic disease (log-rank test, $p = 0.022$). Patients with first metastatic disease at multiple sites had significantly shorter OS compared to each of the other metastatic location groups (log-rank test pairwise comparisons: all $p < 0.04$), while no significant differences with regard to OS were found between patients with bone-only, visceral only, and other site only first metastatic disease (log-rank test pairwise comparisons: all $p > 0.40$).

3.5. CTC Status and Metastatic Site

Compared to patients who were CTC-negative before chemotherapy, CTC-positive patients were numerically more likely to have bone-only first distant disease (25.7% vs. 19.1%) and to have more than one metastatic site at the time first distant recurrence was diagnosed (20.0% vs. 10.3%); the differences between CTC-positive and CTC-negative patients regarding the location of first distant recurrence (bone-only, visceral-only, other site only, multiple sites) were, however, not significant (Chi-squared test, $p = 0.087$; Table 2). Similar proportions were observed with regard to metastatic site at the time of first distant recurrence when only the 159 patients with CTC assessment both before and after chemotherapy were analyzed. CTC-positive patients were numerically more likely to have bone-only first distant disease (23.1% vs. 22.4%) and to have more than one metastatic site at the time first distant recurrence was diagnosed (25.0% vs. 9.3%); however, the differences between CTC-positive and CTC-negative patients regarding the location of first distant re-
currence (bone-only, visceral-only, other site only, multiple sites) were again not significant by a small margin (Chi-squared test, $p = 0.056$; Table 2). Accordingly, the number of CTCs detected before chemotherapy also did not differ significantly among these four metastatic location groups, both when all 206 patients were analyzed (Kruskal–Wallis test, $p = 0.097$) and when only the 159 patients with CTC assessment before and after chemotherapy were analyzed (Kruskal–Wallis test, $p = 0.068$).

Table 2. Association between site of first metastatic disease recurrence and both CTC status at baseline (i.e. before chemotherapy) and CTC status after chemotherapy ($n = 206$: all patients with CTC assessment at baseline, i.e., before chemotherapy; $n = 159$: only patients with CTC assessment both before and after chemotherapy).

| Location of First Distant Recurrence | CTC Status at Baseline ($n = 206$) | CTC Status at Baseline ($n = 159$) | CTC Status after Chemotherapy ($n = 159$) |
|-------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------------|
|                                     | CTC Negative ($n = 136$) | CTC Positive ($n = 70$) | CTC Negative ($n = 107$) | CTC Positive ($n = 52$) | CTC Negative ($n = 115$) | CTC Positive ($n = 44$) |
| Bone only                           | 26 (19.1%) | 18 (25.7%) | 24 (22.4%) | 12 (23.1%) | 23 (20.0%) | 13 (29.5%) |
| Visceral only                       | 45 (33.1%) | 15 (21.4%) | 36 (33.6%) | 12 (23.1%) | 37 (32.2%) | 11 (25.0%) |
| Other site only                     | 51 (37.5%) | 23 (32.9%) | 37 (34.6%) | 15 (28.8%) | 41 (35.7%) | 11 (25.0%) |
| Multiple sites                      | 14 (10.3%) | 14 (20.0%) | 10 (9.3%) | 13 (25.0) | 14 (12.2%) | 9 (20.5%) |

For the 159 patients with CTC assessment after chemotherapy, no association between the site of first metastatic disease and CTC status after chemotherapy was found (Chi-squared test, $p = 0.218$; Table 2) and the number of CTCs detected after chemotherapy also did not differ significantly among these four groups (Kruskal–Wallis test, $p = 0.194$). A comparison of the sites of first metastatic disease among all four CTC change groups revealed differences of borderline significance (Chi-squared test, $p = 0.074$; Table 3). When we compared the CTC pos/pos group with the other three CTC change groups combined, these differences became significant (Chi-squared test, $p = 0.027$), with patients who were CTC-positive at both timepoints more frequently presenting with bone-only first distant disease (37.5% vs. 21.0%) and first distant disease at multiple sites (31.3% vs. 12.6%) compared to patients who were not CTC-positive at both timepoints.

Table 3. Association between site of first metastatic disease recurrence and CTC change group.

| Location of First Distant Recurrence | CTC Change Group ($n = 159$) |
|-------------------------------------|-------------------------------|
|                                     | neg/neg ($n = 79$) | neg/pos ($n = 28$) | pos/neg ($n = 36$) | pos/pos ($n = 16$) |
| Bone only                           | 17 (21.5%) | 7 (25.0%) | 6 (16.7%) | 6 (37.5%) |
| Visceral only                       | 29 (36.7%) | 7 (25.0%) | 8 (22.2%) | 4 (25.0%) |
| Other site only                     | 27 (34.2%) | 10 (35.7%) | 14 (38.9%) | 1 (6.3%) |
| Multiple sites                      | 6 (7.6%) | 4 (14.3%) | 8 (22.2%) | 5 (31.3%) |

4. Discussion

In the present study, we were able to show that the presence of CTCs detected both before and after adjuvant chemotherapy treatment in peripheral blood samples of early breast cancer patients who subsequently developed distant recurrences indicate an increased risk for bone metastases and multi-metastatic disease. Patients with persistently positive CTC status more frequently showed osseous or multiple metastatic disease as compared to patients with discordant or persistently negative CTC status. Patients with first metastatic
disease at multiple sites showed shorter survival compared to patients with first distant recurrence at one site only.

The presence of CTCs before and after chemotherapy is associated with poor prognosis and higher risk for relapse, as these CTCs are interpreted to represent chemotherapy-resistant “minimal residual disease” [9,10]. Furthermore, it could be shown that the presence of CTCs during follow-up, two years after the completion of primary breast cancer treatment, was associated with reduced disease-free and overall survival, especially in patients who demonstrated positive CTC status both before treatment and during follow-up [12]. These results are in line with the concept of the metastatic cascade, which postulates that tumor dormancy, epithelial-to-mesenchymal plasticity, or stemness protect minimal distant residual disease from systemic treatment [4,5,7,38].

As we are able to detect disseminated tumor cells in the bone marrow even before overt metastasis is present, the idea of CTCs and DTCs predicting future metastatic disease, especially in the bones, appears obvious [7,9,39]. Bone not only is a preeminent site for metastasis in the breast but also in prostate cancer and is affected in about 65% to 70% of metastatic patients. Bone is a continuously remodeling organ and the homeostasis between osteoblasts and osteoclasts is governed by systemic estrogen. Metastatic outgrowth is based on aberrant bone remodeling achieved by paracrine crosstalk between DTCs, osteoclasts, and osteoblasts, as well as the bone matrix [40].

Accordingly, data from several large prospective trials suggest that antiresorptive bone treatment with bisphosphonates not only treats bone loss associated with endocrine therapy but also prolongs distant disease-free survival and reduces breast cancer mortality [34,41,42]. In line with these findings, DTC-positive patients treated with bisphosphonates demonstrated a reduction in bone marrow DTCs over time [43,44]. In a stage II/III high-risk breast cancer population treated with adjuvant zoledronate, Neelima et al. recently observed a decline in DTCs and also in CTCs. However, data especially regarding CTC clearance by adjuvant bisphosphonates remain controversial and prospective randomized trials are lacking [31,44]. In the SUCCESS A study, all patients were randomized to receive either 2 or 5 years of adjuvant zoledronic acid treatment (see methods). However, CTC positivity assessed after 5 years did not differ significantly between patients with 2 or 5 years of zoledronate treatment. In addition, the prolonged adjuvant treatment with 5 vs. 2 years of zoledronic acid did not significantly improve disease-free survival, overall survival, and distant disease-free survival [34].

In our analysis, CTC positivity before and after chemotherapy was associated not only with osseous but also with multi-site first metastatic disease, which by itself indicated worse overall survival compared to single-site first distant disease. Multi-metastatic recurrence as first metastatic disease may be explained by tumor heterogeneity and the process of epithelial-mesenchymal transition (EMT). Current studies analyzing single CTCs suggest that they are heterogenous even when harvested from the same individual and therefore belong to different neoplastic subpopulations [3]. Furthermore, they undergo EMT to survive the many bottlenecks on the way to a premetastatic niche, such as the bone marrow. By EMT, these cells lose their epithelial characteristics which makes them more prone to metastasize [38,45]. Especially, this stem-cell-like subpopulation of EMT-affected and metastasis-driving CTCs is missed by the CellSearch system, which detects CTCs according to their epithelial cell adhesion molecule (EpCAM) expression [46].

However, this does not exclude the possibility that EpCAM-positive CTCs form metastatic lesions. Baccelli et al. were able to generate metastatic disease in immunodeficient mice by CellSearch-evaluated CTC-injections. Six recipient rodents developed multiple, visceral, and bone metastases within 6 to 12 months after CTC-injection derived from metastatic breast cancer patients. They concluded that there are different subgroups of CTCs and only a small proportion of cells, so-called metastasis-initiating cells (MIC), has the potential to cause multi-metastatic disease. In line with our clinical data, these MIC originated metastatic lesions occurred in multiple organ systems simultaneously [47].
Our analysis has some limitations. Although the SUCCESS A study was a large trial with 3754 high-risk primary breast cancer patients being recruited, the analysis presented here is based on a small subset of 206 patients, who developed metastatic disease and participated in the translational research project. CTC status at both time points could be assessed in only 159 patients. However, the patients included here were similar with respect to clinico-pathological factors compared to patients with distant disease recurrence that did not participate in the translational research project with CTC assessments; thus, no bias is expected with regard to the associations between CTC status and the site of first metastatic disease found in our study. Due to the small sample size, additional subgroup analysis (e.g., regarding intrinsic tumor subtypes) could not be performed. Furthermore, the group of patients with a positive CTC result both before and after chemotherapy consisted of only 16 patients. On the other hand, these data were derived from a large randomized prospective multicenter quality-controlled clinical trial with a long follow-up period of 64 months. Clearly, more data are needed to confirm our results of an association between CTC status and the site of metastatic disease.

While the independent prognostic potential of CTC testing during treatment and follow-up in breast cancer patients at risk for metastatic disease has been confirmed in several studies [9,11,12], current guidelines counsel against intensified diagnostic testing for metastasis in asymptomatic breast cancer survivors [48,49]. However, taking into account the recent progress in developing new adjuvant add-on treatments, CTC enumeration, profiling, and further characterization may provide important information regarding potential therapeutic targets [46,50].

The clinical use of CTC characterization was assessed in the DETECT study program in a metastatic setting [51]. The screening of 1933 HER2-negative metastatic breast cancer patients for HER2-positive CTCs revealed that 174 (15%) patients out of 1159 CTC-positive patients showed HER2-positive CTCs. In the era of new potent agents like Trastuzumab-Deruxtecan, such CTC characterization can be an important step forward for CTCs to translate from purely prognostic into predictive relevance [52].

CTCs occurrence in peripheral blood samples of early breast cancer patients resembles a low frequency event [53], somewhat limiting the suitability of CTCs as a sole liquid biopsy marker for the detection of minimal residual disease (MRD) during follow-up in early breast cancer survivors. Combining CTC-enumeration with the detection of circulating tumor DNA (ctDNA), shed by tumors during apoptosis, might overcome this problem and considerably increase sensitivity. The prognostic relevance of ctDNA in early breast cancer has been demonstrated in several studies [54,55]. Furthermore, the detection of molecular relapse during breast cancer follow-up via personalized ctDNA profiling has generated a lead-time preceding the clinical detection of metastasis for up to two years. Finally, ctDNA profiling can even identify therapeutic targets, as it just has been established for treatment with alpelisib in ctDNA-PIK3CA mutant metastatic breast cancer patients [56,57].

Whether liquid biopsy is suitable for monitoring and surveillance of breast cancer patients will be assessed in the follow-up trial SURVIVE. The SURVIVE study is a large randomized phase III breast cancer surveillance trial that combines these approaches by using different liquid biopsy markers (CTCs, ctDNA, conventional tumor markers) to evaluate whether an intensified breast cancer follow-up with repeated blood sampling for MRD detection and subsequent early treatment intervention leads to an overall survival benefit as compared to standard follow-up care according to current guidelines. The SURVIVE trial, funded by the German Federal Ministry of Education and Research (BMBF), will start in late 2022 and, if successful, could pave the way for liquid biopsy to enter clinical practice and contribute to a paradigm shift in the current follow-up care of medium- and high-risk early breast cancer survivors.
5. Conclusions

A positive CTC status before and after adjuvant chemotherapy in early breast cancer patients is associated with an enhanced risk of osseous metastatic disease or distant disease recurrence at multiple sites simultaneously. Thus, these patients may be candidates for additional therapeutic interventions and—given the unfavorable prognostic value of first distant disease recurrence at multiple sites—may also benefit from intensified follow-up surveillance to allow early treatment intervention.

Author Contributions: W.J. and B.R designed the study. E.K.T. and T.W.P.F. drafted the manuscript. P.A.F., T.F., A.S., V.M., N.H., R.L., C.S., G.H., F.S., A.d.G., M.T., B.R. and W.J. recruited patients, collected data, and/or provided input for data interpretation. T.W.P.F. and P.A.F. were responsible for the statistical analysis. All authors have read and agreed to the published version of the manuscript.

Funding: Financial support for the SUCCESS A study was provided by AstraZeneca, Chugai, Menarini Silicon Biosystems (formerly Veridex), Lilly, Novartis, Sanofi-Aventis.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the main ethics board Ludwig-Maximilians-University Munich; positive ethics vote 076/05 (NCT 02181101).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: We treasure the commitment and trust of all 3754 patients who participated in the SUCCESS A trial and wholeheartedly thank all of the caregivers who helped these patients become breast cancer survivors.

Conflicts of Interest: E.K.T. declares no conflict of interest. T.W.P.F.: Honoraria from Novartis and Lilly, unrelated to this work. W.J. and B.R declare conflicts of interests: research grants from Menarini Silicon Biosystems. P.A.F. declares no conflict of interests. T.F. declares no conflict of interests. A.S. Gelgene, Roche, AbbVie, Pfizer, Pierre Fabre, Bayer, GSK, Gilead, Tesaro, Lilly, Seagen. N.H. declares no conflict of interests. V.M. speaker honoraria from Amgen, Astra Zeneca, Daiichi-Sankyo, Eisai, Gilead Consultancy honoraria from Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Sanofi, seagen, Gilead Institutional research support from Novartis, Roche, Seagen, Genentech Travel grants: Roche, Pfizer, Daiichi Sankyo, ADG Pfizer, Lilly, DaiichiSankyo, MSD, Astra Zeneca, Tesaro, Roche, Mavie Health GmBH RL declares no conflict of interests. C.S. declares no conflict of interests. G.H. declares no conflict of interests. F.S. declares no conflict of interests. M.T. declares no conflict of interests.

References

1. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [CrossRef] [PubMed]
2. Cobain, E.; Paoletti, C.; Smerage, J.; Hayes, D. Clinical Applications of Circulating Tumor Cells in Breast Cancer. Tumor Liq. Biopsies 2020, 215, 147–160. [CrossRef]
3. Pauken, C.M.; Kenney, S.R.; Brayer, K.J.; Guo, Y.; Brown-Glaberman, U.A.; Marchetti, D. Heterogeneity of Circulating Tumor Cell Neoplastic Subpopulations Outlined by Single-Cell Transcriptomics. Cancers 2021, 13, 4885. [CrossRef]
4. Dujon, A.; Capp, J.-P.; Brown, J.; Pujol, P.; Gatenby, R.; Ujvari, B.; Alix-Panabières, C.; Thomas, F. Is There One Key Step in the Metastatic Cascade? Cancers 2021, 13, 3693. [CrossRef]
5. BalciK-Ercin, P.; Cayrefourcq, L.; Soundararajan, R.; Mani, S.A.; Alix-Panabières, C. Epithelial-to-Mesenchymal Plasticity in Circulating Tumor Cell Lines Sequentially Derived from a Patient with Colorectal Cancer. Cancers 2021, 13, 5408. [CrossRef] [PubMed]
6. Banys-Paluchowski, M.; Reinhardt, F.; Fehm, T. Disseminated Tumor Cells and Dormancy in Breast Cancer Progression. Adv. Exp. Med. Biol. 2020, 1220, 35–43. [CrossRef] [PubMed]
7. Hofbauer, L.; Bozec, A.; Rauner, M.; Jakob, F.; Perner, S.; Pantel, K. Novel approaches to target the microenvironment of bone metastasis. Nat. Rev. Clin. Oncol. 2018, 15, 488–505. [CrossRef]
8. Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W.M.M.; et al. Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. N. Engl. J. Med. 2004, 351, 781–791. [CrossRef]
9. Janni, W.J.; Rack, B.; Terstappen, L.W.M.M.; Pierga, J.-Y.; Taran, F.-A.; Fehm, T.; Hall, C.; de Groot, M.R.; Bidard, F.-C.; Friedl, T.W.P.; et al. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. *Clin. Cancer Res.* 2016, 22, 2583–2593. [CrossRef]

10. Rack, B.; Schindlbeck, C.; Jückstock, J.; Andergassen, U.; Hepp, P.; Zwingers, T.; Friedl, T.W.P.; Lorenz, R.; Tesch, H.; Fasching, P.A.; et al. Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. *JNCI J. Natl. Cancer Inst.* 2014, 106, dju066. [CrossRef]

11. Sparano, J.A.; Gray, R.J.; Ravdin, P.M.; Makower, D.F.; Pritchard, K.I.; Albain, K.S.; Hayes, D.F.; Geyer, C.E.; Dees, E.C.; Goetz, M.L.; Edge, S.B.; Jacobs, L.A.; et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. *J. Clin. Oncol.* 2016, 34, 611–630. [CrossRef]

12. Cochrane Database Syst. Rev. 2016, CD001768. [CrossRef] [PubMed]

13. Royce, M.; Osgood, C.; Mulkey, F.; Bloomquist, E.; Pierce, W.; Roy, A.; Kalavar, S.; Ghosh, S.; Philip, R.; Rizvi, F.; et al. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2022, 40, 1155–1162. [CrossRef] [PubMed]

14. Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kümmel, S.; Bergh, J.; Denkert, C.; Park, Y.; Hui, R.; et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. *N. Engl. J. Med.* 2022, 386, 556–567. [CrossRef] [PubMed]

15. Tutt, A.; Tutt, J.; Kaufman, B.; Viale, G.; Fumagalli, D.; Rastogi, P.; Gelber, R.; de Azambuja, E.; Fielding, A.; Balmaña, J.; et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *N. Engl. J. Med.* 2021, 384, 2394–2405. [CrossRef] [PubMed]

16. Van Mackelenbergh, M.; Seither, F.; Möbus, V.; O’Shaughnessy, J.; Martin, M.; Joensuu, H.; Untch, M.; Nitz, U.; Steger, G.; Miralles, J.; et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy—A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. *Eur. J. Cancer 2022*, 166, 185–201. [CrossRef] [PubMed]

17. Von Minckwitz, G.; Huang, C.; Mano, L.; Loibl, S.; Mamounas, E.; Untch, M.; Wolmark, N.; Rastogi, P.; Schneeweiss, A.; Redondo, A.; et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. *N. Engl. J. Med.* 2019, 380, 617–628. [CrossRef] [PubMed]

18. Sparano, J.A.; Gray, R.J.; Ravdin, P.M.; Makower, D.F.; Pritchard, K.I.; Albain, K.S.; Hayes, D.F.; Geyer, C.E.; Dees, E.C.; Goetz, M.P.; et al. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. *N. Engl. J. Med.* 2019, 380, 2395–2405. [CrossRef]

19. Nitz, U.; Gluz, O.; Graeser, M.; Christgen, M.; Kuemmel, S.; Grischke, E.; Braun, M.; Augustin, D.; Potenberg, J.; Krauss, K.; et al. De-escalated neo-adjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR−): Survival outcomes from a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol.* 2022, 23, 625–635. [CrossRef]

20. Kalinsky, K.; Barlow, W.; Gralow, J.; Meric-Bernstam, F.; Albain, K.; Hayes, D.; Lin, N.; Perez, E.; Goldstein, L.; Chia, S.; et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Negative Breast Cancer. *N. Engl. J. Med.* 2021, 385, 2336–2347. [CrossRef]

21. Ignatiadis, M.; Litière, S.; Rothe, F.; Riethdorf, S.; Proudthon, C.; Fehm, T.; Aalders, K.; Forstbauer, H.; Fasching, P.; Brain, E.; et al. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90901-10093, BIG 1-12, Treat CTC): A randomized phase II trial. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* 2018, 29, 1777–1783. [CrossRef]
30. Naume, B.; Synnestvedt, M.; Falk, R.; Wiedswang, G.; Weyde, K.; Risberg, T.; Kersten, C.; Mjaaland, I.; Vindi, L.; Sommer, H.; et al. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014, 32, 3848–3857. [CrossRef]

31. Neelima, V.; Sally, G.; Laura, P.; Jimmy, H.; Michelle, M.; Goga, A.; Moasser, M.; Magbanua, M.; Park, J.W.; Hugo, H.S. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ Breast Cancer 2021, 7, 113. [CrossRef]

32. Smerage, J.; Barlow, W.; Hortobagyi, G.; Winer, E.; Skalovig, G.; Tejwani, S.; Schott, A.; O’Rourke, M.; Lew, D.; Doyle, G.; et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014, 32, 3483–3489. [CrossRef] [PubMed]

33. De Gregorio, A.; Häberle, L.; Fasching, P.; Müller, V.; Schrader, I.; Lorenz, R.; Forstbauer, H.; Friedl, T.; Bauer, E.; de Gregorio, N.; et al. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res. BCR 2020, 22, 111. [CrossRef] [PubMed]

34. Friedl, T.; Fehm, T.; Müller, V.; Lichtenegger, W.; Blohma, J.; Lorenz, R.; Forstbauer, H.; Fink, V.; Beks, I.; Huober, J.; et al. Prognosis of Patients with Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021, 7, 1149. [CrossRef] [PubMed]

35. Singletary, S.E.; Allred, C.; Ashley, P.; Bassett, L.W.; Berry, D.; Bland, K.I.; Borgen, P.I.; Clark, G.; Edge, S.B.; Hayes, D.F.; et al. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J. Clin. Oncol. 2002, 20, 3628–3636. [CrossRef] [PubMed]

36. Elston, C.W.; Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 2002, 41, 154–161. [CrossRef]

37. Riethdorf, S.; Fritsche, H.; Müller, V.; Rau, T.; Schindlbeck, C.; Rack, B.; Janni, W.; Coith, C.; Beck, K.; Janické, F.; et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13, 920–928. [CrossRef]

38. Trapp, E.K.; Majunke, L.; Zill, B.; Sommer, H.; Andergassen, U.; Koch, J.; Harbeck, N.; Mahner, S.; Friedl, T.W.P.; Janni, W.; et al. LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells. Mol. Oncol. 2017, 11, 1508–1526. [CrossRef]

39. Janni, W.; Vogl, F.; Wiedswang, G.; Synnestevedt, M.; Fehm, T.; Jückstock, J.; Borgen, E.; Rack, B.; Braun, S.; Sommer, H.; et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse—A European pooled analysis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2011, 17, 2967–2976. [CrossRef]

40. Salvador, F.; Llorente, A.; Gomis, R. From latency to overt bone metastasis in breast cancer: Potential for treatment and prevention. J. Pathol. 2019, 249, 6–18. [CrossRef]

41. Coleman, R. Clinical benefits of bone targeted agents in early breast cancer. Breast 2019, 48, S92–S96. [CrossRef]

42. Gralow, J.; Barlow, W.; Paterson, A.; M’iao, J.; Lew, D.; Stopeck, A.; Hayes, D.; Hershman, D.; Schubert, M.; Clemons, M.; et al. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: SO207. J. Natl. Cancer Inst. 2020, 112, 698–707. [CrossRef] [PubMed]

43. Banyas, M.; Solomayer, E.; Gebauer, G.; Janni, W.; Krawczyk, N.; Lueck, H.-J.; Becker, S.; Huober, J.; Kraemer, B.; Wackwitz, B.; et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: Results of a prospective clinical trial. BMC Cancer 2013, 13, 480. [CrossRef]

44. Kasimir-Bauer, S.; Reiter, K.; Aktas, B.; Bittner, A.; Weber, S.; Keller, T.; Kimmig, R.; Hoffmann, O. Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake? Sci. Rep. 2016, 6, 26355. [CrossRef]

45. Dasgupta, A.; Lim, A.R.; Ghajar, C.M. Circulating and disseminated tumor cells: Harbingers or initiators of metastasis? Mol. Oncol. 2017, 11, 40–61. [CrossRef] [PubMed]

46. Heitzer, E.; Haque, I.S.; Roberts, C.E.S.; Speicher, M.R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 2019, 20, 71–88. [CrossRef]

47. Baccelli, I.; Schneeweiss, A.; Riethdorf, S.; Stenzinger, A.; Schillert, A.; Vogel, V.; Klein, C.; Saini, M.; Bäuerle, T.; Wallwiener, M.; et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 2013, 31, 539–544. [CrossRef]

48. Khatcheressian, J.L.; Hurley, P.; Bantug, E.; Esserman, L.J.; Grunfeld, E.; Halberg, E.; Hantel, A.; Henry, N.L.; Muss, H.B.; Smith, T.J.; et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 2013, 31, 961–965. [CrossRef]

49. Runowicz, C.D.; Leach, C.R.; Henry, N.L.; Henry, K.S.; Mackey, H.T.; Cowens-Alvarado, R.L.; Cannady, R.S.; Pratt-Chapman, M.L.; Edge, S.B.; Jacobs, L.A.; et al. American Cancer Society / American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J. Clin. Oncol. 2015, 33, 46–73. [CrossRef]

50. Alix-Panabières, C.; Pantel, K. Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021, 11, 858–873. [CrossRef]

51. Müller, V.; Banys-Paluchowski, M.; Friedl, T.; Fasching, P.; Schneeweiss, A.; Hartkopf, A.; Wallwiener, D.; Rack, B.; Meier-Stiegen, F.; Huober, J.; et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 2021, 6, 100299. [CrossRef] [PubMed]

52. Modi, S.; Jacob, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N.; Prat, A.; Chae, Y.; et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N. Engl. J. Med. 2022, 387, 9–20. [CrossRef] [PubMed]
53. Tibbe, A.G.; Miller, M.C.; Terstappen, L.W. Statistical considerations for enumeration of circulating tumor cells. Cytom. Part. J. Int. Soc. Anal. Cytol. 2007, 71, 154–162. [CrossRef] [PubMed]

54. Cullinane, C.; Fleming, C.; O’Leary, D.P.; Hassan, F.; Kelly, L.; Mj, O.; Ma, C.; Hp, R. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. JAMA Netw. Open 2020, 3, e2026921. [CrossRef]

55. Zhou, Q.; Gampenrieder, S.P.; Frantal, S.; Rinnerthaler, G.; Singer, C.F.; Egle, D.; Pfeiler, G.; Bartsch, R.; Wette, V.; Pichler, A.; et al. Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2022, 28, 697–707. [CrossRef]

56. Burstein, H.J.; Somerfield, M.R.; Barton, D.L.; Dorris, A.; Fallowfield, L.J.; Jain, D.; Johnston, S.; Korde, L.; Litton, J.; Macrae, E.; et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2021, 39, 3959–3977. [CrossRef]

57. Suppan, C.; Graf, R.; Jahn, S.; Zhou, Q.; Klocker, E.V.; Bartsch, R.; Terbuch, A.; Kasher, K.; Regitnig, P.; Lindenmann, J.; et al. Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. Br. J. Cancer 2022, 126, 456–463. [CrossRef]